Genetic modification of T cells for immunotherapy

Bibliography

• KLENERMAN P, HILL A: T cells and viral persistence: lessons from diverse infections. Nat. Immunol. (2005) 6(9):873-879.
   PubMed Web of Science ®Google Scholar
• BLEAKLEY M, RIDDELL SR: Molecules and mechanisms of the graft-versus-leukemia effect. Nat. Rev. Cancer (2004) 4(5):371-380.
   PubMed Web of Science ®Google Scholar
• GALON J, COSTES A, SANCHEZ-CABO F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-1964.
   PubMed Web of Science ®Google Scholar
• DUNN GP, KOEBEL CM, SCHREIBER RD: Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. (2006) 6(11):836-848.
   PubMed Web of Science ®Google Scholar
• WALTER EA, GREENBERG PD, GILBERT MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. (1995) 333(16):1038-1044.
   PubMed Web of Science ®Google Scholar
• PEGGS KS, VERFUERTH S, PIZZEY A et al.: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet (2003) 362:1375-1377.
   PubMed Web of Science ®Google Scholar
• ROONEY CM, SMITH CA, NG CYC et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet (1995) 345:9-13.
   PubMed Web of Science ®Google Scholar
• LEEN AM, MYERS GD, SILI U et al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. (2006) 12(10):1160-1166.
   PubMed Web of Science ®Google Scholar
• BOON T, OLD LJ: Cancer tumor antigens. Curr. Opin. Immunol. (1997) 9(5):681-683.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH J, NISHIMURA MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. (2001) 24(4):363-373.
   PubMed Web of Science ®Google Scholar
• YEE C, THOMPSON JA, BYRD D et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred cells. Proc. Natl. Acad. Sci. USA (2002) 99(25):16168-16173.
   PubMed Web of Science ®Google Scholar
• CURIEL TJ, WEI S, DONG H et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. (2003) 9(5):562-567.
   PubMed Web of Science ®Google Scholar
• CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942-949.
   PubMed Web of Science ®Google Scholar
• SINHA P, CLEMENTS VK, MILLER S, OSTRAND-ROSENBERG S: Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. (2005) 54(11):1137-1142.
   PubMed Web of Science ®Google Scholar
• GROH V, WU J, YEE C, SPIES T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (2002) 419:734-738.
   PubMed Web of Science ®Google Scholar
• BRODERICK L, BANKERT RB: Membrane-associated TGF-β1 inhibits human memory T cell signaling in malignant and nonmalignant inflammatory microenvironments. J. Immunol. (2006) 177(5):3082-3088.
   PubMed Web of Science ®Google Scholar
• GAGGAR A, SHAYAKHMETOV DM, LIEBER A: CD46 is a cellular receptor for group B adenoviruses. Nat. Med. (2003) 9(11):1408-1412.
   PubMed Web of Science ®Google Scholar
• SCHROERS R, HILDEBRANDT Y, HASENKAMP J et al.: Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp. Hematol. (2004) 32:536-546.
   PubMed Web of Science ®Google Scholar
• SAUCE D, BODINIER M, GARIN M et al.: Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein–Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood (2002) 99:1165-1173.
   PubMed Web of Science ®Google Scholar
• FERRAND C, ROBINET E, CONTASSOT E et al.: Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor β-chain hypervariable region repertoire. Hum. Gene Ther. (2000) 11:1151-1164.
   PubMed Web of Science ®Google Scholar
• LENARDO MJ: Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature (1991) 353:858-861.
   PubMed Web of Science ®Google Scholar
• ROBBINS PB, SKELTON DC, YU X-J et al.: Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. USA (1998) 95:10182-10187.
   PubMed Web of Science ®Google Scholar
• WANG L, ROBBINS PB, CARBONARO DA, KOHN DB: High-resolution analysis of cytosine methylation in the 5long terminal repeat of retroviral vectors. Hum. Gene Ther. (1998) 9(16):2321-2330.
   PubMed Web of Science ®Google Scholar
• CAVALIERI S, CAZZANIGA S, GEUNA M et al.: Human T lymphocytes transduced by lentiviral vectors in the absence of TCR-activation maintain an intact immune competence. Blood (2003) 102(2):497-505.
   PubMed Web of Science ®Google Scholar
• ZHOU X, CUI Y, HUANG X et al.: Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum. Gene Ther. (2003) 14:1089-1105.
   PubMed Web of Science ®Google Scholar
• LI Z, DÜLLMANN J, SCHIEDLMEIER B et al.: Murine leukemia induced by retroviral gene marking. Science (2002) 296:497.
   PubMed Web of Science ®Google Scholar
• HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M, LE DEIST F: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. (2003) 348(3):255-256.
   PubMed Web of Science ®Google Scholar
• HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-419.
   PubMed Web of Science ®Google Scholar
• GASPAR HB, PARSLEY KL, HOWE S et al.: Gene-therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gamma retroviral vector. Lancet (2004) 364:2181-2187.
   PubMed Web of Science ®Google Scholar
• PORTEUS MH: Mammalian gene targeting with designed zinc finger nucleases. Mol. Ther. (2006) 13(2):438-446.
   PubMed Web of Science ®Google Scholar
• JENSEN MC, CLARKE P, TAN G et al.: Human T lymphocyte genetic modification with naked DNA. Mol. Ther. (2000) 1(1):49-55.
   PubMed Web of Science ®Google Scholar
• IVICS Z, HACKETT PB, PLASTERK RH, IZSVÁK Z: Molecular reconstitution of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell (1997) 91:501-510.
   PubMed Web of Science ®Google Scholar
• LUO G, IVICS Z, IZSVÁK Z, BRADLEY A: Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA (1998) 95:10769-10773.
   PubMed Web of Science ®Google Scholar
• HUANG X, WILBER AC, BAO L et al.: Stable gene transfer and expression in human primary T-cells by the Sleeping Beauty transposon system. Blood (2006) 107(2):483-491.
   PubMed Web of Science ®Google Scholar
• DEMBIC Z, HAAS W, WEISS S et al.: Transfer of specificity by murine α and β T-cell receptor genes. Nature (1986) 320:232-238.
   PubMed Web of Science ®Google Scholar
• CLAY TM, CUSTER MC, SACHS J et al.: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. (1999) 163:507-513.
   PubMed Web of Science ®Google Scholar
• STANISLAWSKI T, VOSS R-H, LOTZ C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. (2001) 2(10):962-970.
   PubMed Web of Science ®Google Scholar
• MORGAN RA, DUDLEY ME, YU YYL et al.: High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. (2003) 171:3287-3295.
   PubMed Web of Science ®Google Scholar
• KESSELS HWHG, WOLKERS MC, VAN DEN BOOM MD, VAN DER VALK MA, SCHUMACHER TNM: Immunotherapy through TCR gene transfer. Nat. Immunol. (2001) 2(10):957-961.
   PubMed Web of Science ®Google Scholar
• MORGAN RA, DUDLEY ME, WUNDERLICH JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314:126-129.
   PubMed Web of Science ®Google Scholar
• ZHAO Y, ZHENG Z, ROBBINS PF et al.: Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. (2005) 174:4415-4423.
   PubMed Web of Science ®Google Scholar
• MUTIS T, BLOKLAND E, KESTER M, SCHRAMA E, GOULMY E: Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood (2002) 100(2):547-552.
   PubMed Web of Science ®Google Scholar
• XUE S-A, GAO L, HART D et al.: Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood (2005) 106(9):3062-3067.
   PubMed Web of Science ®Google Scholar
• COHEN CJ, ZHAO Y, ZHENG Z, ROSENBERG SA, MORGAN RA: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. (2006) 66(17):8878-8886.
   PubMed Web of Science ®Google Scholar
• KUBALL J, DOSSETT ML, WOLFL M et al.: Facilitating matched pairing and expression of TCR-chains introduced into human T-cells. Blood (2007) 109(6):2331-2338.
   PubMed Web of Science ®Google Scholar
• RICHMAN SA, HEALAN SJ, WEBER KS et al.: Development of a novel strategy for engineering high-affinity proteins by yeast display. Protein Eng. Des. Sel. (2006) 19(6):255-264.
   PubMed Web of Science ®Google Scholar
• PASCHEN A, MÉNDEZ RM, JIMEMEZ P et al.: Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int. J. Cancer (2003) 130:759-767.
   Google Scholar
• YANG L, BALTIMORE D: Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc. Natl. Acad. Sci. USA (2005) 102(12):4518-4523.
   PubMed Web of Science ®Google Scholar
• ESHHAR Z, WAKS T, GROSS G, SCHINDLER DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA (1993) 90:720-724.
   PubMed Web of Science ®Google Scholar
• ROBERTS MR, QIN L, ZHANG D et al.: Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood (1994) 84(9):2878-2889.
   PubMed Web of Science ®Google Scholar
• SADELAIN M, RIVIÈRE I, BRENTJENS RJ: Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer (2003) 3:35-45.
   PubMed Web of Science ®Google Scholar
• BRENTJENS RJ, LATOUCHE J-B, SANTOS E et al.: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. (2003) 9(3):279-286.
   PubMed Web of Science ®Google Scholar
• WESTWOOD JA, SMYTH MJ, TENG MWL et al.: Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl. Acad. Sci. USA (2005) 102(52):19051-19056.
   PubMed Web of Science ®Google Scholar
• KAHLON KS, BROWN C, COOPER LJN et al.: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. (2004) 64:9160-9166.
   PubMed Web of Science ®Google Scholar
• PAMEIJER CRJ, NAVANJO A, MEECHOOVET B et al.: Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. (2007) 14:91-97.
   PubMed Web of Science ®Google Scholar
• GROSS G, WAKS T, ESHHAR Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA (1989) 86(24):10024-10028.
   PubMed Web of Science ®Google Scholar
• ALTENSCHMIDT U, KLUNDT E, GRONER B: Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J. Immunol. (1997) 159:5509-5515.
   PubMed Web of Science ®Google Scholar
• MAHER J, BRENTJENS RJ, GUNSET G, RIVIÈRE I, SADELAIN M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. (2002) 20:70-75.
   PubMed Web of Science ®Google Scholar
• WANG J, PRESS OW, LINDGREN CG et al.: Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol. Ther. (2004) 9(4):577-586.
   PubMed Web of Science ®Google Scholar
• KALERGIS AM, BOUCHERON N, DOUCEY M-A et al.: Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. (2001) 2(3):229-234.
   PubMed Web of Science ®Google Scholar
• HOMBACH AA, SCHILDGEN V, HEUSER C et al.: T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J. Immunol. (2007) 178:4650-4657.
   PubMed Web of Science ®Google Scholar
• FINNEY HM, AKBAR AN, LAWSON ADG: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J. Immunol. (2004) 172:104-113.
   PubMed Web of Science ®Google Scholar
• IMAI C, MIHARA K, ANDREANSKY M et al.: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 18:676-684.
   PubMed Web of Science ®Google Scholar
• ROSSIG C, BOLLARD CM, NUCHTERN JG, ROONEY CM, BRENNER MK: Epstein–Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 99(6):2009-2016.
   PubMed Web of Science ®Google Scholar
• COOPER LJN, AL-KADHIMI Z, SERRANO LM et al.: Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood (2005) 105(4):1622-1631.
   PubMed Web of Science ®Google Scholar
• KERSHAW MH, WESTWOOD JA, HWU P: Dual-specific T cells combine proliferation and antitumor activity. Nat. Biotechnol. (2002) 20:1221-1227.
   PubMed Web of Science ®Google Scholar
• LAMERS CHJ, SLEIJFER S, VILTO AG et al.: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. (2006) 24(13):E20-E22.
   PubMedGoogle Scholar
• BRODIE SJ, LEWINSOHN DA, PATTERSON BK et al.: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. (1999) 5(1):34-41.
   PubMed Web of Science ®Google Scholar
• KERSHAW MH, WESTWOOD JA, PARKER LL et al.: A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. (2006) 12(20):6106-6115.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850-854.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, YANG JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. (2005) 23(10):2346-2357.
   PubMed Web of Science ®Google Scholar
• NAKAMURA TM, MORIN GB, CHAPMAN KB et al.: Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 277:955-959.
   PubMed Web of Science ®Google Scholar
• SHEN X, ZHOU J, HATHCOCK KS et al.: Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. (2007) 30(1):123-129.
   PubMed Web of Science ®Google Scholar
• BODNAR AG, OUELLETTE M, FROLKIS M et al.: Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 279:349-352.
   PubMed Web of Science ®Google Scholar
• DAGARAG M, EVAZYAN T, RAO N, EFFROS RB: Genetic manipulation of telomerase in HIV-specific CD8+ T cells: enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. J. Immunol. (2004) 173(10):6303-6311.
   PubMed Web of Science ®Google Scholar
• VERRA NCV, JORRITSMA A, WEIJER K et al.: Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res. (2004) 64:2153-2161.
   PubMed Web of Science ®Google Scholar
• RÖTH A, BAERLOCHER GM, SCHERTZER M et al.: Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT. Blood (2005) 106(1):43-50.
   PubMed Web of Science ®Google Scholar
• SHRIKANT P, MESCHER MF: Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J. Immunol. (2002) 169(4):1753-1759.
   PubMed Web of Science ®Google Scholar
• EATON D, GILHAM DE, O'NEILL A, HAWKINS RE: Retroviral transduction of human peripheral blood lymphocytes with bcl-xL promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. (2002) 9(8):527-535.
   PubMed Web of Science ®Google Scholar
• CHARO J, FINKELSTEIN SE, GREWAL N et al.: Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. (2005) 65(5):2001-2008.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. (2006) 6:595-601.
   PubMed Web of Science ®Google Scholar
• THOMPSON JA, LEE DJ, LINDGREN CG et al.: Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. (1989) 49:235-240.
   PubMed Web of Science ®Google Scholar
• LIU K, ROSENBERG SA: Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. (2001) 167:6356-6365.
   PubMed Web of Science ®Google Scholar
• LIU K, ROSENBERG SA: Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. (2003) 26(3):190-201.
   PubMed Web of Science ®Google Scholar
• DUBOIS S, MARINER J, WALDMANN TA, TAGAYA Y: IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity (2002) 17:537-547.
   PubMed Web of Science ®Google Scholar
• HSU C, HUGHES MS, ZHENG Z et al.: Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J. Immunol. (2005) 175(11):7226-7234.
   PubMed Web of Science ®Google Scholar
• HSU C, JONES SA, COHEN CJ et al.: Cytokine independent growth and clonal expansion of a primary human CD8+ T cell clone following retroviral transduction with the IL-15 gene. Blood (2007) 109(12):5168-5177.
   PubMed Web of Science ®Google Scholar
• NELSON BH, LORD JD, GREENBERG PD: Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. Nature (1994) 369(6478):333-336.
   PubMed Web of Science ®Google Scholar
• EVANS LS, WITTE PR, FELDHAUS AL et al.: Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-depending growth. Hum. Gene Ther. (1999) 10:1941-1951.
   PubMed Web of Science ®Google Scholar
• CHENG LE, ÖHLÉN C, NELSON BH, GREENBERG PD: Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA (2002) 99(5):3001-3006.
   PubMed Web of Science ®Google Scholar
• BUTCHER EC, PICKER LJ: Lymphocyte homing and homeostasis. Science (1996) 272:60-66.
   PubMed Web of Science ®Google Scholar
• MORA JR, VON ANDRIAN UH: Specificity and plasticity of memory lymphocyte migration. Curr. Top. Microbiol. Immunol. (2006) 308:83-116.
   PubMed Web of Science ®Google Scholar
• OCHSENBEIN AF, SIERRO S, ODERMATT B et al.: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 411:1058-1064.
   PubMed Web of Science ®Google Scholar
• CHEN W, JIN W, HARDEGEN N et al.: Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. (2003) 198(12):1875-1886.
   PubMed Web of Science ®Google Scholar
• VIANELLO F, PAPETA N, CHEN T et al.: Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J. Immunol. (2006) 176:2902-2914.
   PubMed Web of Science ®Google Scholar
• KERSHAW MH, WANG G, WESTWOOD JA et al.: Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. (2002) 13:1971-1980.
   PubMed Web of Science ®Google Scholar
• YEE C, THOMPSON JA, ROCHE P et al.: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. (2000) 192(11):1637-1643.
   PubMed Web of Science ®Google Scholar
• SHU CJ, GUO S, KIM YJ et al.: Visualization of a primary anti-tumor immune response by positron emission tomography. Proc. Natl. Acad. Sci. USA (2005) 102(48):17412-17417.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, ELLIOTT M, LEWINSOHN DA et al.: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. (1996) 2(2):216-223.
   PubMed Web of Science ®Google Scholar
• BERGER C, FLOWERS ME, WARREN EH, RIDDELL SR: Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood (2006) 107(6):2294-2302.
   PubMed Web of Science ®Google Scholar
• LIANG Q, SATYAMURTHY N, BARRIO JR et al.: Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther. (2001) 8:1490-1498.
   PubMed Web of Science ®Google Scholar
• GAJEWSKI TF, MENG Y, BLANK C et al.: Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. (2006) 213:131-145.
   PubMed Web of Science ®Google Scholar
• AHMADZADEH M, ROSENBERG SA: TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. (2005) 174:5215-5223.
   PubMed Web of Science ®Google Scholar
• BOLLARD CM, RÖSSIG C, CALONGE MJ et al.: Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 99(9):3179-3187.
   PubMed Web of Science ®Google Scholar
• LACUESTA K, BUZA E, HAUSER H et al.: Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-β receptor. J. Immunother. (2006) 29(3):250-260.
   PubMed Web of Science ®Google Scholar
• WOLFRAIM LA, FERNANDEZ TM, MAMURA M et al.: Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med. (2004) 351(6):552-559.
   PubMed Web of Science ®Google Scholar
• HAHNE M, RIMOLDI D, SCHROTER M et al.: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 274(5291):1363-1366.
   PubMed Web of Science ®Google Scholar
• CHAMBERS CA, KUHNS MS, EGEN JG, ALLISON JP: CTLA-4 mediated inhibition in regulation of T cell responses: mechanisms and manipulations in tumor immunotherapy. Ann. Rev. Immunol. (2001) 19:565-594.
   PubMed Web of Science ®Google Scholar
• EGEN JG, KUHNS MS, ALLISON JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. (2002) 3(7):611-618.
   PubMed Web of Science ®Google Scholar
• SHARPE AH, WHERRY EJ, AHMED R, FREEMAN GJ: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. (2007) 8(3):239-245.
   PubMed Web of Science ®Google Scholar
• HANNON GJ, ROSSI JJ: Unlocking the potential of the human genome with RNA interference. Nature (2004) 431:371-378.
   PubMed Web of Science ®Google Scholar
• DOTTI G, SAVOLDO B, PULE M et al.: Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood (2005) 105(12):4677-4684.
   PubMed Web of Science ®Google Scholar
• WOLKOWICZ R, NOLAN GP: Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Ther. (2005) 12(6):467-476.
   PubMed Web of Science ®Google Scholar
• MITSUYASU RT, ANTON PA, DEEKS SG et al.: Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood (2000) 96(3):785-793.
   PubMed Web of Science ®Google Scholar
• LEVINE BL, HUMEAU LM, BOYER J et al.: Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA (2006) 103(46):17372-17377.
   PubMed Web of Science ®Google Scholar
• CAVAZZANA-CALVO M, HACEIN-BEY S, DE SAINT BASILE G et al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288:669-672.
   PubMed Web of Science ®Google Scholar
• BONINI C, GREZ M, TRAVERSARI C et al.: Safety of retroviral gene marking with a truncated NGF receptor. Nat. Med. (2003) 9(4):367-369.
   PubMed Web of Science ®Google Scholar
• LAL S, LAUER UM, NIETHAMMER D, BECK JF, SCHLEGEL PG: Suicide genes: past, present and future perspectives. Immunol. Today (2000) 21(1):48-54.
   PubMedGoogle Scholar
• ST.CLAIR MH, LAMBE CU, FURMAN PA: Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob. Agents Chemother. (1987) 31(6):844-849.
   PubMed Web of Science ®Google Scholar
• COHEN JL, BOYER O, SALOMON B et al.: Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood (1997) 89(12):4636-4645.
   PubMed Web of Science ®Google Scholar
• BONINI C, FERRARI G, VERZELETTI S et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 276:1719-1724.
   PubMed Web of Science ®Google Scholar
• SPENCER DM, BELSHAW PJ, CHEN L et al.: Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr. Biol. (1996) 6(7):839-847.
   PubMed Web of Science ®Google Scholar
• MACCORKLE RA, FREEMAN KW, SPENCER DM: Synthetic activation of caspases: artificial death switches. Proc. Natl. Acad. Sci. USA (1998) 95(7):3655-3660.
   PubMed Web of Science ®Google Scholar
• THOMIS DC, MARKTEL S, BONINI C et al.: A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood (2001) 97(5):1249-1257.
   PubMed Web of Science ®Google Scholar
• BERGER C, BLAU CA, CLACKSON T, RIDDELL SR, HEIMFELD S: CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood (2003) 101(2):476-484.
   PubMed Web of Science ®Google Scholar
• BERGER C, BLAU CA, HUANG ML et al.: Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood (2004) 103(4):1261-1269.
   PubMed Web of Science ®Google Scholar
• FAN L, FREEMAN KW, KHAN T, PHAM E, SPENCER DM: Improved artificial death switches based on caspases and FADD. Hum. Gene Ther. (1999) 10:2273-2285.
   PubMed Web of Science ®Google Scholar
• STRAATHOF KC, PULÈ MA, YOTNDA P et al.: An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 105(11):4247-4254.
   PubMed Web of Science ®Google Scholar
• FRANK O, RUDOLPH C, HEBERLEIN C et al.: Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood (2004) 104(12):3543-3549.
   PubMed Web of Science ®Google Scholar